United States Patent 7,695,734: Scope, Claim Construction, and Competitive Landscape for Pramipexole Extended-Release Tablets
What is US 7,695,734 claiming at the core?
US 7,695,734 centers on an extended-release (ER) pramipexole tablet where release is driven by a dual-polymer hydrophilic matrix that creates pH-selective drug release in defined media, specifically:
- Higher release at pH < 4.5 (tested in simulated gastric juice pH 1.2)
- Lower release from pH 4.5 to 7.5 (tested in McIlvaine buffer pH 4.5 and phosphate buffer pH 6.8)
The formulation is defined by a strict polymer architecture:
- Matrix contains at least two water-swelling hydrophilic polymers
- Polymers exclude pregelatinized starch (no pregelatinized starch in the formulation)
- One polymer is anionic
- The other polymer is substantially neutral
- pH-dependent behavior is linked to polymer composition:
- Anionic polymer: ~0.5 wt.% to ~15 wt.%
- Neutral polymer: ~25 wt.% to ~65 wt.%
Claims also tie product performance to formulation testing conditions and to manufacturing pathways that support commercial replicability (direct compression; wet granulation; dry granulation), with optional particle engineering (peg-milling).
What is the independent claim scope? (Claim 1)
Claim 1 sets the broadest composition and performance requirements.
Claim 1, essentials
- Dosage form: extended release tablet (matrix tablet)
- Drug: pramipexole or a pharmaceutically acceptable salt
- Matrix polymers:
- At least two water-swelling hydrophilic polymers
- No pregelatinized starch
- At least one anionic polymer
- Other polymer is substantially neutral
- Polymer performance:
- pH-dependent release rate
- In pH < 4.5 range: release rate is higher
- In pH 4.5 to 7.5 range: release rate is lower
- Tested in:
- simulated gastric juice pH 1.2
- McIlvaine buffer pH 4.5
- phosphate buffer pH 6.8
- Polymer loading windows:
- anionic polymer ~0.5 to ~15 wt.%
- neutral polymer ~25 to ~65 wt.%
This is a functional, medium-defined ER release profile claim. The polymer blend is the mechanism, and the pH media are the performance anchor.
What are the main dependent claim “switches” that narrow scope?
The patent builds a lattice of dependent claims that narrow product identity and manufacturing method without abandoning the core dual-polymer / pH behavior framework.
Polymer identity constraints
Claim 2
- Anionic polymer selected from:
- optionally crosslinked acrylic acid polymers
- carboxymethyl cellulose
Claim 3
- Anionic polymer is optionally crosslinked acrylic acid polymer
Claim 4
- Optional crosslinked acrylic acid polymer is loaded at:
Claim 5
- Neutral polymer selected from:
- hydroxypropyl cellulose
- hydroxypropyl methyl cellulose
Claim 6
- Neutral polymer is hydroxypropyl methyl cellulose
Matrix compositional ranges (structural claim support)
Claim 7
- Matrix composition includes:
- 0.05 to 5 wt.% pramipexole or salt
- 0.5 to 15 wt.% anionic water swelling polymer(s)
- 25 to 65 wt.% neutral water swelling polymer(s)
- remainder excipients up to 100%
This range is consistent with claim 1 but explicitly includes drug wt.% limits.
Specific “consisting of” embodiments
Two “consisting of” claims lock ingredient lists tightly.
Claim 8
- “Consisting of”:
- pramipexole dihydrochloride monohydrate
- hypromellose 2208
- corn starch
- Carbomer 941
- colloidal silicon dioxide
- magnesium stearate
Claim 19
- “Consisting of” with ranges:
- 0.1 to 2% pramipexole (or salt)
- 25 to 65% HPMCs (hypromellose is the class; claim text says hydroxypropyl methyl cellulose)
- 0 to 40% CMC sodium
- 0 to 75% corn starch
- 0.5 to 15% acrylic polymerisate
- 0.5 to 50% excipients
Claim 20
- Same as claim 19, plus:
- optionally a non-functional coating as the only coating
Claims 21-26
- Convert acrylic polymerisate into carbomer 941
- Constrain excipient selections to a fixed enumerated set (silicon dioxide, magnesium stearate, lactose monohydrate, mannitol, MCC, dibasic anhydrous calcium phosphate, hydroxypropyl cellulose, povidone, copovidone, talc, macrogols, sodium dodecylsulfate, iron oxides, titanium dioxide)
Claim 27
- Combines the dual-polymer and performance framework with:
- coating constraint: either no coating or only non-functional coating
- exclusion of pregelatinized starch
- anionic and neutral polymer loading windows remain
Coating boundary
Claim 17
Claim 18
- non-functional coating only
These claims matter because a functional coating could be used by competitors to change release behavior without touching matrix chemistry.
Drug content and dosing
Claims 9
- ER tablet contains sufficient drug for a daily dose administered once
Claims 29-31
- pramipexole (or salt) content ranges:
- ~0.05 to 5 wt.% (claim 29)
- ~0.1 mg to 10 mg (claim 30)
- ~0.1 mg to 5 mg (claim 31)
What manufacturing steps does the patent try to pre-empt?
Claims 10-16 (method claims) add a second layer of enforceability. They require:
- dual-polymer matrix (anionic + neutral; no pregelatinized starch)
- pH media performance
- polymer loading windows
- and explicit manufacturing processes
Three process families are claimed:
Direct compression process
Claim 10
- Active trituration with portion of water-swelling polymer(s) and/or excipients; pramipexole is milled prior to use
- Premix main portion polymers/excipients
- Optional dry screening for content uniformity
- Mix with remaining excipients
- Tablet press compression to matrix tablets
Claim 11
- pramipexole is peg-milled prior to use
Wet granulation process
Claim 12
- Blend pramipexole with portion excipients; pramipexole milled prior to use
- Granulation liquid added (explicit options in dependent claims)
- Dry granules (fluid bed or oven)
- Mix dried granules with polymers/excipients
- Compress to matrix tablets
Claim 13
- pramipexole peg-milled prior to use
Claim 14
- granulation liquid is water
Dry granulation process
Claim 15
- Mix pramipexole with fillers/excipients; pramipexole milled prior to use
- Compaction with roller compactor
- Mill/sieve ribbons into granules
- Optional mixing with remaining excipients
- Compress granules (or final blend) to matrix tablets
Claim 16
- pramipexole peg-milled prior to use
Practical meaning: even if a competitor changes manufacturing route (direct vs granulation), the patent anticipates multiple standard routes.
What is the likely claim construction strategy for enforcement?
From the claim structure, US 7,695,734 is positioned to capture both:
- Composition variants that still keep the dual-polymer mechanism and pH release pattern; and
- Process variants that still produce the same ER behavior.
Key enforcement levers:
- Performance definition via specific pH media and directionality: release rate at pH<4.5 must be higher than at pH 4.5-7.5.
- Polymer class split: one anionic, one substantially neutral.
- No pregelatinized starch: removes an easy formulation substitute.
- Loading ranges: provide quantitative guardrails for design-around.
- Optional coating boundary: only none or non-functional coatings.
How broad is the “design space” competitors have?
Competitors can try to avoid infringement by changing at least one mandatory axis. The patent’s structure suggests the following risk-mapped design-around options:
Axis A: Replace the anionic polymer or remove anionic character
This is likely the highest-risk route because claim 1 requires anionic + neutral polymer pairing.
- If the anionic polymer class is removed entirely, the product may fall outside claim 1’s required anionic presence.
- But dependent claims constrain anionic types to acrylic acid polymers and CMC; claim 1 itself only requires anionic polymer generally.
Axis B: Use neutral polymer types outside the recited examples
Claim 1 only requires “substantially neutral polymer.” Claims 5-6 list preferred examples (HPC/HPMC). So substituting neutral polymers can be a route, but must preserve the pH release pattern.
Axis C: Modify polymer loading outside the windows
Claim 1 is quantitative:
- anionic: 0.5-15 wt.%
- neutral: 25-65 wt.%
Shifting outside these ranges is a direct design-around. However, that can be difficult while maintaining the ER and pH-differential behavior.
Axis D: Retain polymers but alter release behavior
Claim 1’s performance direction is mandatory:
- release at pH<4.5 must be higher than at 4.5-7.5.
A competitor can attempt to flatten the pH response (more pH-independent across the full range), but then the product avoids the claim’s functional limitation.
Axis E: Use pregelatinized starch
This is a clear exclusion in claim 1.
If a competitor uses pregelatinized starch in the matrix, it likely avoids claim 1 as written, but must ensure the rest of the formulation (dual polymer or otherwise) does not fall into another dependent “consisting of” embodiment that still permits corn starch but not pregelatinized starch. The claims are explicit: “does not contain pregelatinized starch.”
Axis F: Functional coating
Claims 17-18 narrow coating options:
- no coating
- or non-functional coating only
A functional coating that alters release could be an escape route if it changes the release mechanism sufficiently and avoids the claim’s implied dependence on matrix behavior alone.
Competitive patent landscape: what matters around this patent?
Even without asserting individual document families, the practical landscape for pramipexole ER is defined by recurring patent themes:
- ER dosage form strategy for pramipexole (tablet formulations)
- Hydrophilic matrix technology (HPMC/HPC, carbomers, acrylic polymers, CMC)
- pH-responsive or pH-influenced release (ionizable polymer systems)
- Starch use and substitution (pregelatinized starch explicitly excluded in this patent)
- Manufacturing method pre-emption (direct compression vs granulation routes)
- Particle engineering (peg-milling language)
Within this framework, US 7,695,734 is positioned as a matrix-and-performance specific patent with an unusually explicit pH release profile and hard composition ranges.
Freedom-to-operate implications (claim coverage map)
Below is a coverage map keyed to likely competitor modifications.
| Competitor change |
Claim 1 likely affected element |
Likely infringement risk direction |
| Remove anionic polymer entirely |
Breaks required “at least one anionic polymer” |
Lower risk if release mechanism remains ER but matrix no longer meets claim 1 |
| Keep anionic + neutral, but load outside 0.5-15 wt.% / 25-65 wt.% |
Breaks quantitative polymer loading |
Lower risk if clearly outside ranges |
| Use pregelatinized starch in matrix |
Breaks “does not contain pregelatinized starch” |
Lower risk if present as required by claim language |
| Keep same matrix polymers but engineer pH profile to be flat or reversed |
Breaks functional performance: higher release at pH<4.5 |
Lower risk if performance fails required directionality |
| Use functional coating to dominate release |
Potentially avoids “non-functional coating only” limitations in dependent claims; claim 1 still allows no restriction but performance must match |
Mixed: depends whether claim 1 is interpreted to require uncoated matrix behavior or performance still meets pH test limits |
| Switch direct compression to wet granulation |
Covered by process claims (10-16) if performance and formulation match |
Higher risk: patent anticipates multiple manufacturing routes |
| Switch to a different milling method for drug |
Covered as peg-milling only in dependent claims 11/13/16; claim 10/12/15 just requires milled prior to use |
Lower risk for the peg-milled sub-scope; higher risk if the broader formulation still matches |
Key actionable takeaways for R&D and licensing
- The patent’s “center of gravity” is a dual-polymer hydrophilic ER matrix that is explicitly pH-responsive with a defined directional release profile across pH 1.2, 4.5, 6.8.
- The formulation is controlled by hard quantitative windows for anionic and neutral polymer wt.%.
- Pregelatinized starch is excluded, narrowing common matrix substitutions.
- The patent includes process claims across direct compression, wet granulation, and dry granulation, reducing the value of switching manufacturing route as a design-around.
- The dependent claims create additional “lock-in” combinations using:
- HPMC (hypromellose 2208)
- Carbomer 941
- Acrylic polymerisate
- optional non-functional coating
- and enumerated excipient lists
Key Takeaways
- US 7,695,734 is enforceable around a specific ER mechanism: pramipexole in a water-swelling matrix with anionic + substantially neutral polymers, tuned to produce higher release at pH < 4.5 than from pH 4.5 to 7.5, tested in pH 1.2 / 4.5 / 6.8 media.
- Claim 1 is broad on polymer identity but strict on structure and performance: it requires dual-polymer chemistry, excludes pregelatinized starch, and locks in polymer wt.% ranges.
- Dependent claims tighten design space through specific polymer exemplars (carboxymethyl cellulose; optionally crosslinked acrylic acid polymers; HPMC/HPC) and “consisting of” ingredient lists (notably including Carbomer 941 and hypromellose 2208).
- Process claims reduce route-based design-around value by covering direct compression, wet granulation, and dry granulation, with optional peg-milling.
FAQs
1) Does US 7,695,734 require a coating?
No. Claim 1 does not require a coating. Dependent claims specify either no coating or a non-functional coating only (claims 17-18), and coating is also addressed in “consisting of” embodiments (claims 20 and 27).
2) Can a competitor use a different anionic polymer than CMC or crosslinked acrylic acid?
Claim 1 requires an anionic polymer but does not limit the anionic polymer to the dependent claim exemplars. Risk increases if the alternative maintains the same pH-release directionality and polymer loading windows.
3) Is pregelatinized starch allowed?
No. Claim 1 explicitly requires the formulation does not contain pregelatinized starch. That is a direct exclusion.
4) Does changing manufacturing method avoid the patent?
Not if the final tablet matches the claim-limited formulation and performance. The patent includes method claims covering direct compression, wet granulation, and dry granulation.
5) What pH test conditions are used in the performance limitations?
The claims specify:
- simulated gastric juice pH 1.2
- McIlvaine buffer pH 4.5
- phosphate buffer pH 6.8
And they require release at pH < 4.5 to be higher than at pH 4.5 to 7.5.
References
[1] United States Patent No. 7,695,734.
